Study guide

5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

Key Takeaways Explain This Topic AI

Retinoblastoma presents with leukocoria or strabismus; germline RB1 disease raises bilateral and trilateral (pineal) risk, and leukocoria needs urgent ophthalmology rather than a family photograph used as diagnosis.

Retinoblastoma local therapy ranges from exam under anesthesia with focal measures to intra-arterial or intravitreal chemotherapy, systemic chemotherapy, or enucleation; radiation raises second-tumor risk especially in germline RB1.

Hepatoblastoma is an infant and toddler liver tumor with rising AFP, PRETEXT staging, and links to prematurity and Beckwith-Wiedemann syndrome; cisplatin-based therapy aims at resection, with transplant for unresectable disease, and ototoxicity surveillance is mandatory.

Malignant germ-cell tumors secrete AFP and/or beta-hCG; sites include infant sacrococcygeal tumors, adolescent gonadal tumors, mediastinal tumors in males with Klinefelter risk, and intracranial primaries.

BEP-like therapy uses bleomycin, etoposide, and cisplatin; watch bleomycin pulmonary toxicity with pulse oximetry and avoid unnecessary high inspired oxygen, while mature teratoma is treated with surgery rather than extra chemotherapy.

Last updated: August 2026

A parent shows a holiday photograph in which one pupil is white instead of red. That is leukocoria , not a camera trick to file under “mention at the 18-month well-child visit.” The same week, a 14-month-old has a firm liver edge and an alpha-fetoprotein (AFP) in the tens of thousands, and a 16-year-old with Klinefelter syndrome has a mediastinal mass and a rising beta-human chorionic gonadotropin (beta-hCG). CPHON Domain II.A still expects you to handle these “other” solid tumors: retinoblastoma, hepatoblastoma, and germ-cell tumors. They are not rare enough to skip, and their nursing traps—urgent eye referral, cisplatin hearing loss, bleomycin lungs, marker surveillance—are high-yield.

Retinoblastoma: leukocoria is not a photograph diagnosis

Retinoblastoma is a malignant retinal tumor of infants and toddlers. Classic signs are leukocoria (white pupil) and strabismus . Less often, a red, painful eye or orbital inflammation is the first story. Do not let a family photograph of the red reflex become the diagnostic plan. A missing red reflex on a flash photo is a reason to obtain urgent pediatric ophthalmology , not a social-media diagnosis and not a six-month wait. The nurse’s script is: same-week specialist exam, not “try another camera.”

Biology is the RB1 tumor-suppressor gene and the two-hit model. Germline RB1 pathogenic variants (heritable disease) present earlier, are often bilateral or multifocal, and carry risk of trilateral disease—an intracranial primitive neuroectodermal tumor, classically in the pineal region. Sporadic non-germline disease is usually unilateral and later. Every newly diagnosed child needs a genetics conversation; “only one eye is involved” does not prove the child is non-germline. Germline patients need ongoing dilated exams of the fellow eye and brain imaging surveillance for pineal disease as the protocol specifies.

Staging and treatment happen largely during exam under anesthesia with a retinoblastoma ophthalmologist: mapping tumors, focal laser or cryotherapy, and decisions about intra-arterial or intravitreal chemotherapy, systemic chemotherapy (commonly vincristine, etoposide, and carboplatin), or enucleation when vision cannot be saved or when extrascleral or anterior-chamber disease demands it. Radiation can control residual intraocular or extraocular disease but raises second-tumor risk , especially osteosarcoma and other sarcomas in germline RB1 carriers. Avoid teaching radiation as a casual first step for a germline infant with salvageable eyes.

Nursing around intra-arterial chemotherapy includes groin-access care, limb-perfusion checks, and the same fever rules as any myelosuppressive cycle when systemic exposure occurs. After enucleation, teach socket care, prosthetic timing, and the emotional weight of an infant’s missing eye without implying the family “waited too long” if they came as soon as leukocoria was noticed.

Hepatoblastoma: infants, AFP, PRETEXT, cisplatin, transplant

Hepatoblastoma is the most common primary liver malignancy of childhood. It is a disease of infants and toddlers . The mass may be found because the abdomen looks full, a caregiver feels a firm liver, or a screening ultrasound is done in Beckwith-Wiedemann syndrome . Prematurity is another epidemiologic association. AFP is typically markedly elevated and then becomes the tumor marker for response and relapse. Do not use a single AFP number in isolation in a neonate without context—newborn AFP is normally high and falls—but a toddler with a liver mass and a rising or very high AFP is hepatoblastoma until the sarcoma team says otherwise.

PRETEXT (PRE-Treatment EXTent of disease) stages how many of the four liver sections are involved and whether there is venous, extrahepatic, or metastatic disease. The therapeutic goal is complete resection . Cisplatin-based chemotherapy (often with doxorubicin on cooperative-group regimens) shrinks tumors toward resectability. Ototoxicity is the nursing organ to protect: serial audiology, developmental hearing follow-up, and classroom advocacy. Nephrotoxicity and magnesium wasting travel with cisplatin as in osteosarcoma. When PRETEXT III/IV or vascular involvement leaves the tumor unresectable after neoadjuvant therapy, liver transplant at a pediatric transplant center is curative-intent therapy, not a last-ditch hospice maneuver. Do not tell a family that an unresectable liver mass automatically means palliation only.

Hepatocellular carcinoma is the different older-child liver tumor, often with underlying liver disease and a less chemosensitive course. Keep hepatoblastoma in the infant/toddler, high-AFP, PRETEXT, cisplatin, resect-or-transplant box.

Germ-cell tumors: site, markers, BEP, mature teratoma

Pediatric germ-cell tumors (GCTs) follow age and anatomy.

Sacrococcygeal tumors present in fetuses and infants as a rump or pelvic mass (sometimes mainly internal). Malignant elements are often yolk-sac tumor; AFP is the marker. Resection includes the coccyx . Residual coccyx is a relapse trap.

Gonadal tumors present in adolescents : painless testicular enlargement, or an ovarian mass with pain or torsion. Never teach “wait and see if the teen’s testis swelling is a sports strain” without ultrasound and tumor markers.

Mediastinal GCTs in adolescent males associate with Klinefelter syndrome . A boy with a huge anterior mediastinal mass, gynecomastia, and rising beta-hCG needs airway caution plus a genetics note, not a casual lymphoma induction assumption.

Intracranial GCTs sit in pineal or suprasellar regions: Parinaud syndrome and hydrocephalus at the pineal, diabetes insipidus and visual or pituitary failure at the suprasellar cistern. Markers can be measured in serum and cerebrospinal fluid.

AFP tracks yolk-sac elements (and hepatoblastoma, so interpret with the primary site). Beta-hCG tracks choriocarcinoma and some germinomas. Falling markers confirm response; plateau or rise during therapy is residual or refractory disease until proven otherwise. Mature teratoma is a surgical disease. Chemotherapy does not reliably shrink mature teratoma; growing-teratoma physiology after markers normalize is an operative problem, not an automatic extra bleomycin cycle.

Malignant GCT chemotherapy is BEP-like : bleomycin , etoposide , cisplatin . Bleomycin pulmonary toxicity is the distinctive nursing hazard. Monitor pulse oximetry and respiratory symptoms. Teach families that a new dry cough or dyspnea is same-day evaluation. Communicate with anesthesia: avoid unnecessary high inspired oxygen . Do not treat every post-operative desaturation with casual high-flow oxygen “just in case” without a plan. Etoposide adds myelosuppression and a late secondary-leukemia conversation. Cisplatin again means ears and kidneys.

A 6-month-old with a sacrococcygeal mass and a high AFP, a 15-year-old with a testicular mass, and a boy with Klinefelter syndrome and a mediastinal GCT share markers and BEP lung precautions—but not the same surgical field. Keep site, marker, and mature-versus-malignant straight at the bedside.

Tumor Typical age / clue Marker or gene Treatment nursing focus

Retinoblastoma Infant/toddler leukocoria or strabismus Germline vs sporadic RB1; trilateral pineal risk Urgent ophthalmology, EUA, enucleation vs focal vs intra-arterial/intravitreal vs systemic chemo; radiation second-tumor risk in germline disease

Hepatoblastoma Infant/toddler liver mass; prematurity or Beckwith-Wiedemann Markedly elevated AFP; PRETEXT stage Cisplatin-based chemo, audiology, resect when possible, transplant if unresectable

  • Sacrococcygeal GCT Infant rump/pelvic mass AFP if yolk-sac elements Resect tumor and coccyx; markers
  • Gonadal GCT Adolescent testis or ovary AFP and/or beta-hCG Do not delay ultrasound; BEP-like if malignant
  • Mediastinal GCT Adolescent male, Klinefelter risk beta-hCG ± AFP Airway, markers, bleomycin lung precautions
  • Mature teratoma Any GCT site Markers usually negative Surgery; extra chemotherapy does not replace resection

Typical pediatric age window for these solid tumors